Avanza Fonder AB Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN

Avanza Fonder AB boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.8% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 10,597 shares of the biopharmaceutical company’s stock after purchasing an additional 860 shares during the quarter. Avanza Fonder AB’s holdings in Regeneron Pharmaceuticals were worth $5,958,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Activest Wealth Management raised its stake in shares of Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 21 shares during the period. Saudi Central Bank acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at about $31,000. Traub Capital Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $38,000. Finally, Berbice Capital Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 300.0% in the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 60 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. The trade was a 9.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the transaction, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $779.70 on Friday. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $792.77. The stock’s 50 day simple moving average is $699.36 and its 200 day simple moving average is $607.79. The firm has a market cap of $81.95 billion, a P/E ratio of 18.67, a P/E/G ratio of 2.25 and a beta of 0.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same period in the prior year, the company earned $12.46 earnings per share. The firm’s revenue was up .9% compared to the same quarter last year. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

Wall Street Analysts Forecast Growth

REGN has been the topic of several analyst reports. Bank of America raised their target price on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an “underperform” rating in a report on Wednesday, October 29th. Scotiabank lifted their price objective on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research note on Monday, November 24th. Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the company an “equal weight” rating in a research note on Friday, December 12th. Finally, Truist Financial started coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, November 24th. They set a “buy” rating and a $798.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $779.45.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.